# Kadmon Corporation, LLC clinical trials: 20 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Kadmon Corporation, LLC as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Kadmon Corporation, LLC: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/kadmon-corporation-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 3, 2021 | NCT04735822 | A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability | Kadmon Corporation, LLC | Early phase 1 | Completed | Healthy Volunteers | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04735822) |
| April 9, 2019 | NCT03907540 | Human Absorption, Distribution and Metabolism Study (hAME) \[14C\]-KD025 | Kadmon Corporation, LLC | Phase 1 | Completed | Autoimmune Diseases, Fibrosis | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03907540) |
| May 21, 2018 | NCT03530995 | Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers | Kadmon Corporation, LLC | Phase 1 | Completed | Drug-drug Interaction, Autoimmune Diseases, Fibrotic Disease | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03530995) |
| March 30, 2017 | NCT03096080 | A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney... | Kadmon Corporation, LLC | Phase 1 | Completed | Polycystic Kidney, Autosomal Recessive | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03096080) |
| August 2, 2016 | NCT02852967 | A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque... | Kadmon Corporation, LLC | Phase 2 | Completed | Chronic Plaque Psoriasis | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02852967) |
| July 26, 2016 | NCT02844439 | Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma | Kadmon Corporation, LLC | Phase 2 | Completed | Glioblastoma, Recurrent Glioblastoma, Brain Tumor | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02844439) |
| February 23, 2016 | NCT02688647 | A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis | Kadmon Corporation, LLC | Phase 2 | Completed | Idiopathic Pulmonary Fibrosis | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02688647) |
| November 26, 2015 | NCT02616393 | Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases | Kadmon Corporation, LLC | Phase 2 | Completed | Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02616393) |
| November 26, 2015 | NCT02616055 | Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 | Kadmon Corporation, LLC | Phase 2 | Terminated | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02616055) |
| September 23, 2015 | NCT02557139 | Bioavailability of Belumosudil (KD025) in Healthy Male Subjects | Kadmon Corporation, LLC | Phase 1 | Completed | Bioavailability | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02557139) |
| December 16, 2014 | NCT02317627 | Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy | Kadmon Corporation, LLC | Phase 2 | Completed | Psoriasis Vulgaris | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02317627) |
| June 3, 2014 | NCT02154529 | Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Kadmon Corporation, LLC | Phase 1/2 | Terminated | HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02154529) |
| April 8, 2014 | NCT02106195 | A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris | Kadmon Corporation, LLC | Phase 2 | Completed | Psoriasis Vulgaris | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02106195) |
| December 7, 2011 | NCT01487174 | KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy | Kadmon Corporation, LLC | Phase 3 | Terminated | Carcinoma, Non-Small-Cell Lung | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01487174) |
| August 4, 2009 | NCT00951223 | Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C | Kadmon Corporation, LLC | Observational | Withdrawn | Hepatitis C | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00951223) |
| August 29, 2007 | NCT00522145 | Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib | Kadmon Corporation, LLC | Phase 2 | Completed | Carcinoma, Non-Small-Cell Lung | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00522145) |
| April 4, 2007 | NCT00456248 | Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin | Kadmon Corporation, LLC | Phase 4 | Terminated | Hepatitis C | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00456248) |
| August 16, 2006 | NCT00364780 | Study of XL647 in Subjects With Non-Small-Cell Lung Cancer | Kadmon Corporation, LLC | Phase 2 | Completed | Non-small-cell Lung Cancer | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00364780) |
| June 14, 2006 | NCT00336765 | Study of XL647 Administered Orally Daily to Patients With Solid Tumors | Kadmon Corporation, LLC | Phase 1 | Completed | Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00336765) |
| July 7, 2004 | NCT00086528 | Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors | Kadmon Corporation, LLC | Phase 1 | Completed | Cancer | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00086528) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 9 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 15 |
| Terminated | 4 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Brain Neoplasms | 3 |
| Autoimmune Diseases | 2 |
| Fibrosis | 2 |
| Hepatitis C | 2 |
| Neoplasms | 2 |
| Polycystic Kidney, Autosomal Recessive | 1 |
| Polycystic Kidney Diseases | 1 |
| Glioblastoma | 1 |
| Hepatitis C, Chronic | 1 |
| Meningeal Carcinomatosis | 1 |
| Idiopathic Pulmonary Fibrosis | 1 |
| Pulmonary Fibrosis | 1 |
| Idiopathic Interstitial Pneumonias | 1 |
| Lung Diseases | 1 |
| Polycystic Kidney, Autosomal Dominant | 1 |
| Skin Diseases | 1 |
| Plaque, Amyloid | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric pulmonology practices in the United States](https://specstream.ai/data/businesses/pediatric-pulmonology-practices/united-states)
- [Fence contractors in the United States](https://specstream.ai/data/businesses/fence-contractors/united-states)
- [Argentine restaurants in the United States](https://specstream.ai/data/businesses/argentine-restaurants/united-states)
- [Pizza restaurants in the United States](https://specstream.ai/data/businesses/pizza-restaurants/united-states)
- [Fish and chips restaurants in the United States](https://specstream.ai/data/businesses/fish-and-chips-restaurants/united-states)
- [Auto lenders in the United States](https://specstream.ai/data/businesses/auto-lenders/united-states)
